Previous 10 |
home / stock / crpof / crpof news
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery systems - - Third quarter 2019 sales and nine-month 2019 sales respectively increased 36.9% and 28.5% vs ...
EDMONTON, Alberta, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc . ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare an...
EDMONTON, Alberta, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic indu...
NEW YORK , Oct. 16, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a growth-stage biotechnology company focused on the development and commercializa...
Ceapro ( OTC:CRPOF ): Q2 GAAP EPS of -$0.01. More news on: Ceapro Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
Ceapro ( OTC:CRPOF ): Q1 GAAP EPS of -$0.01. More news on: Ceapro Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
The following slide deck was published by Ceapro Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...